idelalisib

May 25, 2016May 25, 2016

Idelalisib for Indolent Non-Hodgkin Lymphoma a Viable Option, Review Finds

News

In a comprehensive review of idelalisib (Zydelig) treatment for patients with indolent non-Hodgkin lymphoma, Hofstra University’s Jacqueline C Barrientos concluded that the drug is a promising option in patients who have already been ... Read more

January 19, 2016January 19, 2016

Promising Follicular Lymphoma Treatments Include New Agents and Drug Combinations

News

Lymphoma, the most common category of blood cancer, has two main forms: Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). There are six types of Hodgkin’s lymphoma, but some 85 percent of diagnosed ... Read more

May 29, 2015September 4, 2015

Scottish Medicine Consortium Approves Zydelig For Follicular Lymphoma

News

Gilead Sciences, Inc. recently announced the Scottish Medicines Consortium (SMC) approved Zydelig (idelalisib) for the treatment of follicular lymphoma. Zydelig is a new first-in-class drug indicated as a monotherapy for the treatment of adult patients ... Read more